WPG Advisers’s Maravai LifeSciences MRVI Stock Holding History

WPG Advisers’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-396	Closed	-$2.16K	–	1507
2024 Q4	$2.16K	Buy	+396	New	+$2.55K	﹤0.01%	1061

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WPG Advisers's MRVI Position: Q1 2025 in Review

WPG Advisers sold out of Maravai LifeSciences (MRVI) in Q1 2025, closing a stake of 396 shares — an estimated $2.16K sold.

WPG Advisers first reported a position in MRVI in Q4 2024 and held it in 1 quarter. The position peaked at $2.16K in Q4 2024. 184 funds tracked by Wall St. Rank hold MRVI as of Q1 2025.

WPG Advisers reported no remaining Maravai LifeSciences position as of Q1 2025 after selling out during the quarter.
WPG Advisers sold 396 Maravai LifeSciences shares in Q1 2025, an estimated $2.16K.
WPG Advisers first reported a position in Maravai LifeSciences in Q4 2024 and held it in 1 quarter.
WPG Advisers's Maravai LifeSciences position peaked at $2.16K in Q4 2024.
184 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2025.

Based on WPG Advisers's 13F filing for Q1 2025, filed 15 May 2025.